Information Provided By: 
Fly News Breaks for March 14, 2019
VSTM
Mar 14, 2019 | 07:28 EDT
H.C. Wainwright analyst Swayampakula Ramakanth lowered his price target for Verastem to $10 from $13 saying that while the Copiktra launch progressing, the early ramp is slower than expected. The analyst, however, continues to believe in the long-term potential of Copiktra and reiterates a Buy rating on the shares.
News For VSTM From the Last 2 Days
VSTM
Apr 18, 2024 | 16:05 EDT
Verastem Oncology "announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience, to chief medical officer where he will lead the Company's clinical and medical strategy. Dr. Hayslip succeeds Louis J. Denis, M.D., who recently departed the company. Dr. Hayslip has more than 25 years of oncology and research and development experience across industry and academia, most recently serving as the chief medical officer at I-MAB Biopharma. "
